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Ribosome biogenesis during cell cycle arrest fuels
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Ribosome biogenesis is a canonical hallmark of cell growth and proliferation. Here we show
that execution of Epithelial-to-Mesenchymal Transition (EMT), a migratory cellular program
associated with development and tumor metastasis, is fueled by upregulation of ribosome
biogenesis during G1/S arrest. This unexpected EMT feature is independent of species and
initiating signal, and is accompanied by release of the repressive nucleolar chromatin
remodeling complex (NoRC) from rDNA, together with recruitment of the EMT-driving
transcription factor Snai1 (Snail1), RNA Polymerase I (Pol I) and the Upstream Binding Factor
(UBF). EMT-associated ribosome biogenesis is also coincident with increased nucleolar
recruitment of Rictor, an essential component of the EMT-promoting mammalian target of
rapamycin complex 2 (mTORC2). Inhibition of rRNA synthesis in vivo differentiates primary
tumors to a benign, Estrogen Receptor-alpha (ERα) positive, Rictor-negative phenotype and
reduces metastasis. These findings implicate the EMT-associated ribosome biogenesis pro-
gram with cellular plasticity, de-differentiation, cancer progression and metastatic disease.
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Metastasis is the leading cause of breast cancer-associatedmortality1. The mechanisms underlying metastasis,including the orchestrated programs coordinating the
migration and dissemination of primary tumor cells to distal
tissues, remain unclear2. The EMT program is an exemplar of
cellular plasticity that de-differentiates epithelial cells to a stem-
like mesenchymal phenotype to promote cell migration in
development and disease3–5. Like other differentiation and ded-
ifferentiation programs6, EMT is characterized by cell cycle arrest
and the cessation of proliferation7,8.
Pervasive reprogramming of both transcription and translation
during EMT endows the cell with pro-migratory, invasive prop-
erties3–5,9. Transcriptional changes are mediated, in part, by
EMT-associated transcription factors, including Snail1/2, Smads,
ZEB1, and Twist3–5. The EMT program is implicated in the
initiating steps of malignancy and the resistance of tumor cell
subpopulations to anti-proliferative chemotherapies3,10. Corre-
spondingly, a deeper understanding of the regulation and
execution of EMT has the potential to expand our knowledge of
disease progression and the repertoire of treatment strategies used
to combat metastatic disease.
EMT can be induced by a variety of physiological signals3,5.
The induction of EMT by transforming growth factor beta
(TGFβ) occurs via activation of Smad-dependent and Smad-
independent signaling pathways11,12. Smad-independent signal-
ing can activate mTORC2, a multicomponent protein complex
that includes the adaptor protein Rictor and the mammalian
stress-activated protein kinase interaction protein 1 (mSin1)12.
mTORC2 activation is linked to its association with the
ribosome13,14, the two-subunit RNA–protein complex respon-
sible for cellular protein synthesis.
Ribosome biogenesis occurs in the nucleolus and is initiated by
transcription of rDNA operons by RNA polymerase I (Pol I). The
three major rRNA constituents of the ribosome (5.8S, 18S and
28S rRNAs) are generated by Pol I15. The fourth rRNA compo-
nent (5S rRNA), as well as the transfer RNA (tRNA) substrates
used in protein synthesis, are transcribed by Pol III16.
Active ribosome biogenesis is regulated in a cell cycle-
dependent manner15 and is typically associated with cell growth
and division17. Ribosome biogenesis increases the size of
nucleolar organizing regions (NORs) which have long been used
as a marker of tumor cell proliferation that negatively correlates
with patient survival17–19. The induction of rDNA transcription
is also associated with cellular plasticity, dedifferentiation, and
stemness20. Given that approximately half of all rDNA operons
are silenced in differentiated cells by the repressive TTF-I inter-
acting protein 5 (TIP5)-associated, NoRC21, we hypothesized that
the de-differentiating EMT program may be accompanied by
changes in rDNA transcription. In this context, we set out to
examine whether ribosome biogenesis contributes to EMT and
metastatic cancer progression.
Here, we show that the induction of ribosome biogenesis is a
general feature of the EMT program. Activation of ribosome
biogenesis, the mesenchymal gene expression program, and a
migratory phenotype is concurrent with NoRC dissociation from
rDNA, together with increased expression and association of Pol
I, the Pol I-transcription factor UBF, and the EMT-promoting
transcription factor Snail1, with rDNA. Consistent with ribosome
biogenesis being a necessary feature of EMT, pharmacological
inhibition and genetic knockdown of Pol I lowered the abundance
of pro-invasive mesenchymal proteins and reduced cellular
invasiveness. In line with mTORC2 activation driving EMT
through physical interactions with the ribosome13,14, we further
show that TGFβ-driven EMT induces rRNA-dependent associa-
tion of Rictor with nucleoli.
In mouse models of metastatic breast cancer, the suppression
of Pol I-mediated transcription by CX-5461, a clinical-stage small
molecule that inhibits Pol I assembly at rDNA operons22–24,
reduced the metastatic potential of primary tumors as well as
metastatic seeding. These impacts correlated with decreased
Snail1 and Rictor abundance and increased Cytokeratin 8/18
(CK8/18) and Estrogen Receptor-alpha (ERα) protein levels,
indicative of tumor differentiation. Elevated rRNA synthesis was
also evidenced in invasive, dedifferentiated human breast cancers,
including triple-negative tissues, compared to ERα+ tumor tis-
sues and normal breast tissues. These findings collectively indi-
cate that the EMT-associated ribosome biogenesis program fuels
cellular plasticity and migration and that targeting this program
can induce tumor differentiation in a manner that may poten-
tially restore or enhance patient responsiveness to established
endocrine therapies.
Results
rRNA synthesis is induced in vitro and in vivo during EMT. To
investigate rRNA synthesis during EMT, we initially employed
the NMuMG cell line, a well-established EMT model system
where epithelial cells transition to a mesenchymal state within 48
h of TGFβ treatment25. As expected25, at 48 h TGFβ-induced
NMuMG cells displayed reduced expression of the epithelial
marker E-cadherin (Cdh1), as well as coxsackie and adenovirus
receptor (Cxadr or CAR) proteins (Fig. 1a; Supplementary
Fig. 1a–c). They also exhibited elevated expression of the
mesenchymal proteins N-cadherin (Cdh2) and Vimentin (Vim)
(Fig. 1a; Supplementary Fig. 1a–c), increased stress fiber forma-
tion (Phalloidin staining) (Supplementary Fig. 1a), as well as
increased transcription and nuclear localization of the EMT
transcription factors Snail1, Smad4, and Twist (Fig. 1a; Supple-
mentary Fig. 1a, c). In line with the previous literature7,8, parallel
pulse treatment with 5-ethynyl-2′-deoxyuridine (EdU), an
established marker of DNA synthesis26, showed TGFβ treatment
to reduce cellular proliferation by 7-fold (Fig. 1a, b). The non-
proliferative status of NMuMG cells in the mesenchymal state
was further evidenced by reduced cell division and reduced
expression of the proliferation marker Ki6727 (Supplementary
Fig. 1d–f).
To assess nascent RNA synthesis in epithelial and mesench-
ymal cell populations, the majority of which is rRNA28,29, we
briefly pulsed proliferating (Control) and TGFβ-treated (48 h)
NMuMG cells with 5-Fluorouridine (FUrd) (Methods). These
experiments revealed that FUrd levels were >2 fold higher in the
TGFβ-treated cell population and highly localized to the
nucleolus (Fig. 1a, b). Cells exhibiting increased nucleolar FUrd
staining were generally non-overlapping with those incorporating
EdU (Supplementary Fig. 1g, h), consistent with TGFβ-induced
rRNA synthesis being independent of cell proliferation. While
specific mesenchymal proteins increased in abundance upon
TGFβ treatment (Fig. 1a; Supplementary Fig. 1a, b), the induction
of rRNA synthesis during EMT was concomitant with a modest
decrease in global protein synthesis (Fig. 1a, b; Methods).
To substantiate the finding that EMT is accompanied by rRNA
synthesis during a halt in proliferation, we examined the Py2T
mammary cell line derived from the MMTV-PyMT mouse
model, which also undergoes EMT within 48 h of TGFβ
stimulation30. Confirming their transition to a mesenchymal
state, TGFβ-treated Py2T cells (48 h) displayed significant
reductions of E-cadherin and CAR levels, increased Vimentin
and Snail1 abundance, and enhanced stress fiber formation
(Supplementary Fig. 1i). Mesenchymal Py2T cells also exhibited a
concomitant increase in nucleolar FUrd incorporation together
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with marked reductions in EdU incorporation and Ki67
expression (Fig. 1c; Supplementary Fig. 1j).
To exclude the possibility that these observations were unique
to TGFβ-mediated EMT in mouse cells, we employed the human
MCF7 breast cancer cell line, which undergoes hypoxia-induced
EMT via Notch signalling31. MCF7 cells grown for 48 h under
hypoxic conditions exhibited both decreased E-cadherin and
increased nuclear Snail1 abundance (Supplementary Fig. 1k),
characteristic of a mesenchymal state. As observed for both
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exhibited increased nucleolar FUrd incorporation and a reduction
in the number of EdU+ cells (Fig. 1d; Supplementary Fig. 1l).
To corroborate these findings in vivo, we investigated the
extent of rRNA and DNA synthesis during the delamination and
migration of neural crest cells in chick and mouse embryonic
development8. Neural crest cells are multipotent progenitor cells
that undergo Wnt-driven EMT to facilitate migration from the
dorsal neural tube to distinct regions throughout the embryo
where they differentiate to epidermal, skeletal, nervous, and
connective tissues8. To visualize nascent rRNA and DNA
synthesis in the chick, embryos were pulsed with FUrd and
EdU during early stages of neural crest migration (at Hamburger
and Hamilton stage 18/19; Methods). Consistent with an
upregulation of rRNA synthesis, delaminating and migrating
neural crest cells—identified by positive Snai2 (Snail2)
staining8,32—exhibited increased nuclear FUrd incorporation,
particularly along neural crest migratory routes (Fig. 1e). By
contrast, Snail2 expression was largely absent in non-migrating,
proliferating (EdU+) cells throughout the neural tube (Fig. 1f).
Mouse embryos similarly pulsed with ethynyl uridine (EU;
rRNA synthesis33) and 5-bromo-2′-deoxyuridine (BrdU; DNA
synthesis) at embryonic day 9.0 (E9.0) (Methods), showed that
cells exhibiting high-levels of rRNA synthesis were non-
overlapping with those exhibiting high-levels of DNA synthesis
(Fig. 1g). Delaminating neural crest cells within the dorsal neural
tube had higher levels of rRNA synthesis than migratory neural
crest cells (defined by the expression of transcription factor
Sox1034) (Fig. 1g). These findings collectively indicate that
increased rRNA synthesis is a general hallmark of the EMT
program (Fig. 1h).
rRNA synthesis induction parallels EMT execution. To examine
whether increased rRNA synthesis coincides with execution of the
EMT program, or if it is a feature of the mesenchymal end state,
we examined rRNA synthesis in NMuMG cells 27, 48 and 96 h
after TGFβ treatment (Fig. 1i, j; Supplementary Fig. 1m). After 27
h, Vimentin abundance was increased compared to proliferating
(Control) cells, while E-cadherin levels remained unchanged
(Fig. 1i; Supplementary Fig. 1n). These findings suggest that
execution of the EMT program has only partially completed at
this time point. Concomitantly, NMuMG cells displayed
decreased DNA synthesis and increased rRNA synthesis (Fig. 1i, j;
Supplementary Fig. 1m). We conclude from these data that the
induction of rRNA synthesis is closely timed with onset of the
EMT program.
At 48 h of TGFβ treatment, EdU incorporation reached a
minimum, which was partially regained after 96 h; FUrd
incorporation peaked at 48 h and then declined at 96 h (Fig. 1i, j;
Supplementary Fig. 1m). Confirming continuation of the EMT
program, E-cadherin expression progressively decreased while
Vimentin expression further increased (Fig. 1i; Supplementary
Fig. 1n). Both EdU and FUrd incorporation decreased over time in
proliferating cells, paralleling increased cell confluence (Fig. 1i, j;
Supplementary Fig. 1m). We therefore conclude that the EMT
program is hallmarked by a divergence in rRNA and DNA
synthesis, where rRNA synthesis is transiently induced while DNA
synthesis is halted. After EMT is complete, mesenchymal cells then
reduce rRNA synthesis to resume proliferation (Fig. 1j).
EMT is accompanied by increased ribosome biogenesis. Sup-
porting the notion that the induction of rRNA synthesis during
EMT is concomitant with increased ribosome biogenesis, 45S pre-
rRNA transcript levels reached the highest point in NMuMG cells
after 48 h of TGFβ treatment (Fig. 2a). The observed increase in
45S rRNA expression levels correlated with NOR sizes, which
were greater than those observed in proliferating (Control) cells
(Fig. 2b). Elevated ribosome biogenesis at 48 h was further con-
firmed by the induction of 34S, 28S, 18S and 5.8S processed
rRNA transcripts (Supplementary Fig. 2a–d). As expected for
active ribosome biogenesis15,35, the increases in rRNA processing
observed were concomitant with an increase in the mRNA and
protein expression levels of core components of the Pol I tran-
scriptional machinery, including Pol I subunits, UBF, the RNA
Pol I-specific transcription initiation factor, RRN3 (Rrn3), the
ribosome biogenesis-associated proteins Nucleolin (Ncl) and B23
(Npm1), the 45S processing factor and the rRNA methyl-
transferase Fibrillarin (Fbl), and the Pol I-activating NAD-
dependent histone deacetylase Sirtuin 7 (SIRT7) (Fig. 2c; Sup-
plementary Fig. 2e–g).
Ribosome biogenesis in EMT occurs during cell cycle arrest. As
cell cycle arrest has been reported to accompany EMT initiation
and execution7,8, we used FUCCI technologies36 to investigate the
relationship between the observed increase in rRNA synthesis and
cell cycle regulation. As anticipated37, after 48 h of TGFβ treat-
ment, NMuMG cells were found to arrest and synchronize at the
G1/S transition (Fig. 2d). In line with increased rRNA synthesis,
they also displayed enlarged UBF-marked nucleoli compared to
proliferating cells (Fig. 2d, inset). Corroborating arrest at the G1/S
transition, we simultaneously observed a global decrease in cyclin
D1 levels as well as increased levels of nuclear cyclin E (Supple-
mentary Fig. 2h), which together coordinate S phase entry38.
Evidence supporting increased ribosome biogenesis and cell cycle
arrest coincident with the EMT program was also found in TGFβ-
induced Py2T cells and hypoxia-induced MCF7 cells (Supple-
mentary Fig. 2i, j) as well as in delaminating, migrating neural
crest cell populations in mouse8 (Fig. 2e). We conclude from
these findings that the level of ribosome biogenesis that accom-
panies EMT during cell cycle arrest at the G1/S transition is
greater than that which normally occurs at this stage of the
cell cycle.
Fig. 1 Enhanced rRNA synthesis during EMT is independent of cell proliferation. a Proliferating (Control) and 48 h TGFβ-treated (TGFβ) NMuMG cells
immunostained for E-cadherin, Vimentin, Snail1, DNA synthesis (EdU), rRNA synthesis (FUrd), and nascent peptide synthesis (AHA) (green). b FUrd, EdU,
and AHA quantifications from a, P < 0.01, P < 0.001, P < 0.05. c Quantifications of FUrd and EdU in Py2T cells ± TGFβ, P < 0.04, P < 0.04. d Quantifications
of FUrd and EdU in MCF7 cells ± hypoxia-induced EMT, P < 0.001, P < 0.05. e Immunostaining of FUrd (green), Snail2 (red), and DAPI (blue) in
delaminating/migrating neural crest cells (white arrows) of the chick neural tube. Representative inset of the neural crest delaminating region is included.
f Immunostaining of EdU (green), Snail2 (red), and DAPI (blue) in the chick neural tube with a representative inset of the neural crest delaminating region.
g Immunostaining of Sox10 (green), DNA synthesis (BrdU, red), and rRNA synthesis (EU, cyan) in mouse E9.0 neural tube. Migrating neural crest cells are
indicated with white arrows. h Illustration of neural crest delamination/migration showing patterns of detected rRNA (green, left half) and DNA synthesis
(red, right half). i Immunostaining of E-cadherin (green), Vimentin (green), colocalization of RNA synthesis (FUrd, green) with DNA synthesis (EdU, red),
and brightfield images at 27, 48, 96 h ± TGFβ in NMuMG cells. j Illustration of quantified rRNA/DNA synthesis (FUrd/EdU) time course from (i) in Control
(proliferation) and TGFβ (EMT) conditions. Red and green shapes depict FUrd (P < 0.01) and EdU (P < 0.02) quantifications. All error bars ± SE, n= 3.
Asterisk denotes t-test significance at P≤ 0.05. Scale bar for all images= 50 µm
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The EMT program activates normally silenced rDNA operons.
Mammalian cells possess hundreds of highly homologous, tan-
demly repeated, rDNA operons39. The precise sequences of these
rDNA operons are not known and it has yet to be determined if,
or how, the distinct mammalian rRNA alleles are differentially
regulated in response to physiological stimuli39. A significant
portion of rDNA operons are silenced through NoRC-regulated
heterochromatin formation to ensure nucleolar integrity and
genomic stability21. NoRC promotes transcriptional down-
regulation by actively recruiting DNA methyltransferases to
mediate epigenetic silencing21. Regulated changes in rRNA
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transcription from already activated rDNA operons or by
decreasing the number that are repressed21.
To determine whether the increase in ribosome biogenesis
accompanying EMT reflects the activation of rDNA hetero-
chromatin, we examined the expression and localization of
TIP521 in proliferating and TGFβ-treated NMuMG cells. Western
blot analysis showed a global increase in nuclear TIP5 levels
following 48 h of TGFβ treatment (Supplementary Fig. 2k).
Chromatin immunoprecipitation (ChIP) experiments revealed,
however, that such changes were accompanied by reduced TIP5
association with rDNA promoters (Fig. 2f). Interestingly, and in
line with altered E-cadherin and Snail1 expression levels during
EMT (Fig. 1a; Supplementary Fig. 2a–c), ChIP analysis revealed
reduced TIP5 association with the Snail1 promoter while TIP5
association increased at the E-cadherin promoter (Cdh1) (Fig. 2f).
Corroborating the release of NoRC from rDNA during EMT,
TGFβ treatment significantly reduced rDNA promoter methyla-
tion (Fig. 2g). These changes were concomitant with an induction
of H3K4Me3 and H3K27Ac epigenetic marks, which are
canonically associated with actively transcribed genes21,40, at
rDNA promoters and both 28S and 18S rRNA genes (Fig. 2h).
These findings indicate that the relocalization of NoRC during
EMT contributes to the transcriptional regulation of Pol I-
mediated gene expression. ChIP studies further confirmed an
increased recruitment of the core components of Pol I
transcription machinery, including Pol I, UBF and SIRT7, to
rDNA promoter regions and the 18S and 28S rRNA genes
(Fig. 2i, j), consistent with the activation of rRNA expression. We,
therefore, conclude that the increase in ribosome biogenesis
accompanying EMT is associated with an opening of rDNA
operons that are at least partially silenced in proliferating cells,
which represent the differentiated, epithelial state.
Snail1 regulates rRNA synthesis during EMT. Concomitant
with Snail1’s established recruitment to the E-cadherin
promoter3,25 (Supplementary Fig. 2l), ChIP experiments unex-
pectedly revealed that Snail1 is also recruited to rDNA repeats in
a TGFβ-dependent manner (Fig. 2l). To assess whether Snail1
regulates rRNA synthesis, Snail1 levels were induced in NMuMG-
Snail1-ERT2 cells by the addition of 4-hydroxytamoxifen41
(Methods). In this system, Snail1 induction resulted in a partial
EMT, indicated by modest reduction in E-cadherin expression
and modest, but significant, increases in rRNA synthesis,
nucleolar UBF, and Fibrillarin staining (Fig. 2l). These findings
demonstrate that Snail1 contributes to the regulation of rRNA
synthesis and ribosome biogenesis during EMT.
Inhibition of ribosome biogenesis halts EMT. To specifically
examine whether ribosome biogenesis is required for cells to
transition from an epithelial to a mesenchymal state, we sought to
abruptly attenuate rRNA synthesis during EMT by pharmacolo-
gical means22. To do so, we employed CX-5461, an established
small-molecule inhibitor of Pol I complex assembly at rDNA
promoters, and thus the initiation of ribosome
biogenesis22,24,35,42.
For these experiments, we chose a CX-5641 concentration
(100 nM) that had little to no impact on rRNA synthesis and
ribosome biogenesis in proliferating cells, as measured by FUrd
incorporation and 45S rRNA levels (Fig. 3a, b). This concentra-
tion is an order of magnitude lower than what has been
previously used to block ribosome biogenesis and DNA synthesis
in proliferating cells, which induces nucleolar stress, increases
nuclear p53 levels and arrests cells in G1 and G2/M22–24.
Notably, the administration of CX-5461 (100 nM) to TGFβ-
treated NMuMG cells (27 h) significantly reduced FUrd incor-
poration and 45S pre-rRNA transcription (Fig. 3a, b). In this
setting, we observed little to no change in the already suppressed
levels of EdU incorporation (Fig. 3c), consistent with TGFβ-treated
cells already exhibiting a cessation of DNA synthesis at the time
point of CX-5461 administration (27 h) (Fig. 1i, j; Supplementary
Fig. 1m). We also observed no effect on nuclear p53 levels
(Supplementary Fig. 3a), a canonical marker for nucleolar stress,
cell cycle (Supplementary Fig. 3b), or nucleolar UBF localization
(Supplementary Fig. 3b). By contrast, the DNA damaging agent,
aphidicolin43 (APH; 10 µM), reduced DNA synthesis but had no
measurable impacts on rRNA synthesis or Snail1 levels (Supple-
mentary Fig. 3c). CX-5461 also exerted only modest impacts on
γH2X levels, a readout of both ATM/ATR signaling and DNA
damage24,42 (Supplementary Fig. 3c).
ChIP studies further revealed that CX-5461 blocked the TGFβ-
induced association of UBF and Snail1 with rDNA (Fig. 3d). CX-
5461 also significantly reduced the abundance of key mesench-
ymal markers known to promote the EMT program, including
Vimentin, Snail1, and stress fibers, as well as significantly reduce
the migratory and invasive capacities of TGFβ-treated cells
(Fig. 3e–g). At the same time, CX-5461 had no significant impacts
on E-cadherin mRNA or protein levels (Supplementary Fig. 3d),
while modestly lowering TGFβ-induced impacts on apoptosis and
autophagy (Supplementary Fig. 3e, f). Hence, in the context of
TGFβ-mediated cell cycle arrest, CX-5461 (100 nM) mediates the
inhibition of ribosome biogenesis to specifically halt the gain of
mesenchymal traits associated with EMT, while having no
measurable impacts on nucleolar integrity or stress.
Effects of a globally similar nature were also observed when
analogous experiments were performed on TGFβ-treated cells
using low doses of actinomycin D (Act D; 0.01 µg/mL), which
selectively inhibits the elongation phase of Pol I-mediated rRNA
synthesis and ribosome biogenesis at low concentrations24. Act D
did, however, exhibit distinctions from CX-5461 in regards to its
more pronounced reductions of rRNA and DNA synthesis and
cell invasion in both proliferating and TGFβ-treated cells
Fig. 2 Characteristic features of the EMT-associated ribosome biogenesis program. Cell culture experiments in b–k depict proliferating (Control) and TGFβ-
treated (TGFβ) NMuMG cells at 48 h assessing changes with treatment. a qRT-PCR of 45S (pre)-rRNA transcript at 24, 48 and 72 hrs (h), P < 0.015.
b Silver staining of nucleolar organizer regions (NORs). c Immunostaining of Pol I, UBF, RRN3, Nucleolin, B23, and Fibrillarin (all green). d Cell cycle analysis
of proliferating and TGFβ-treated NMuMG cells using the FUCCI technology, DAPI (blue), S/G2/M (geminin, green) and G1 (Cdt1, red), UBF (magenta)
and merged. Colocalized green and red fluorescence indicates G1/S arrest (yellow). e rRNA synthesis (EU, red), Pol I (green) and merged (yellow) in the
mouse neural crest. NT= neural tube, highlighted by white dotted box. f ChIP analysis of TIP5 binding to the rDNA, E-cadherin (Cdh1) and Snail1
promoters, P < 0.03. g HpaII methylation assay of the rDNA promoter, P < 0.007. h ChIP analysis of H3K4Me3 and H3K27Ac marks to the rDNA
promoter, 18S rDNA and 28S rDNA, P < 0.006 and P < 0.005. i ChIP analysis of Pol I and UBF binding to rDNA promoter, 18S rDNA and 28S rDNA, P <
0.015 and P < 0.04. j ChIP analysis of SIRT7 binding to rDNA promoter, 18S rDNA and 28S rDNA, P < 0.005. k ChIP analysis of Snail1 binding to rDNA
promoter, 18S rDNA, and 28S rDNA, P < 0.03. l Snail1 (green), E-cad (green), EU (red). Fibrillarin (green), UBF (green) and DAPI (blue) in proliferating
(Control) and inducible Snail1 overexpression in NMuMG cells. Quantification of EU, P < 0.0002. All error bars ± SD, n= 3. Asterisk denotes t-test
significance. Scale bar for all images= 50 µm
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(Supplementary Fig. 3g, h). Act D also had no significant impact
on Vimentin protein levels in the TFGβ context (Supplementary
Fig. 3h). These distinctions may relate to Act D’s unique mode of
ribosome biogenesis inhibition, which disrupts active Pol I
transcription.
To further verify the role of ribosome biogenesis during EMT,
we partially silenced the large subunit of Pol I (Polr1a) using
RNAi (Methods). Although this approach compromised cell
viability, this experiment confirmed that genetic depletion of Pol I
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Vimentin expression (Supplementary Fig. 3i) and invasion
(Supplementary Fig. 3j). These results are consistent with
ribosome biogenesis being required for execution of the EMT
program.
The impacts of CX-5461 on EMT-associated ribosome bio-
genesis. Consistent with CX-5461ʼs distinct impacts on pro-
liferating and TGFβ-treated NMuMG cells, gene expression
analyses on the actively translating ribosome pool (Methods)
revealed that CX-5461-regulated genes were predominantly
(~80%) non-overlapping between proliferating and TGFβ-treated
cells (Supplementary Fig. 3k). Gene Ontology (GO) analysis44
further revealed that the subset of genes commonly upregulated
by CX-5461 were enriched for those involved in translation
(3.6e−18), while commonly downregulated genes were not
enriched for any annotated GO category. Hence, CX-5461 has
distinct impacts on gene expression in proliferating and TGFβ-
treated cells although ribosome biogenesis is a common
denominator in both systems.
The EMT-associated ribosome biogenesis is linked to Rictor.
mTORC2 is a key driver of EMT45, whose activation is mediated
through ribosome association13,14. Given the observed necessity
of ribosomal biogenesis for execution of the EMT program, we
investigated the potential connection between rRNA synthesis
and mTORC2 signaling through the assessment of the Rictor
component of mTORC213,46. As expected13, prior to the treat-
ment of NMuMG cells with TGFβ, Rictor predominantly loca-
lized to filamentous structures in the cytoplasm and to the
endoplasmic reticulum (ER), indicated by its colocalization with
the ER marker Calnexin (Fig. 3h). Consistent with mTORC2
activation during EMT45, Rictor exhibited a pronounced increase
in ER localization following 48 h of TGFβ treatment (Fig. 3h).
Strikingly, Rictor also showed a pronounced increase in
nucleolar localization upon TGFβ treatment (Fig. 3h), which
was specifically abolished by RNase treatment prior or subsequent
to fixation (Fig. 3i, Supplementary Fig. 3l). Consistent with its
association with nascent rRNA transcripts, Rictor localization to
nucleoli was reduced by CX-5461 administration (100 nM) after
27 hrs of TGFβ treatment (Fig. 3h, Supplementary Fig. 3m). In
line with reduction in mTORC2 signaling and disruption of the
EMT program45, CX-5461 also diminished Rictor’s association
with the ER (Fig. 3h). Notably, CX-5461 exerted no changes on
the mRNA transcript levels of Rictor or the mTORC2-regulated
mesenchymal markers Vimentin and Snail1 (Fig. 3j). Smad4
expression also remained unchanged (Supplementary Fig. 3n).
Pol I and Rictor levels increase during tumor progression. We
next examined the relevance of rRNA synthesis to tumor growth
and metastasis in the MMTV-PyMT mouse. This model system
mimics the development of human luminal breast cancer pro-
gression from focal hyperplasia through adenoma into early and
late carcinomas with a progressive loss of luminal markers and
hormonal receptor expression that metastasize to the lung47.
Hematoxylin and Eosin (H&E) staining of MMTV-PyMT mouse
mammary luminal tumors at 6 weeks showed hyperplastic
regions with minimally invasive characteristics (Fig. 4a). At this
stage, which is prior to metastasis (Fig. 4a), only low levels of Pol I
expression were observed in the hyperplasic areas (Fig. 4b). At
8 weeks of age, areas of the mammary glands displayed adenoma-
like tumors and micro-metastases were also detected in the lung
(Fig. 4a; Supplementary Fig. 4a). By 12 weeks, basal carcinoma-
like tumors, typical of a poor prognostic outcome, were detected
with highly invasive characteristics, including extensive stromal
and immune cell infiltration47 (Fig. 4a). At 8- and 12-week
assessment points, we observed prominent staining of Pol I that
was notably enhanced at invasive tumor fronts (Fig. 4b, white
arrows). The observed increase in rRNA synthesis correlated with
an increase in Rictor protein levels, as evidenced by immuno-
histochemical staining (IHC) (Supplementary Fig. 4b). By con-
trast, Ki67 staining gradually decreased with tumor progression
(Fig. 4b), indicating that the observed increased rRNA synthesis
was occurring within the largely non-proliferative primary tumor
region. At 12 weeks, strong Pol I staining was also observed
within secondary lung metastases (Supplementary Fig. 4c).
Similar patterns of Pol I and Ki67 levels were also observed in
both primary mammary tumors and secondary lung metastases
in the basal-like medullary adenocarcinoma E0771 mouse
model48 (Fig. 4c; Methods). These data corroborate our in vitro
findings and indicate that Pol I expression is induced within
largely non-proliferative tumor cell populations in distinct mouse
models representing distinct subtypes of breast cancer during
disease progression.
Ribosome biogenesis inhibition induces tumor differentiation.
To investigate the role of rRNA synthesis in cancer invasion,
spread, and metastasis, MMTV-PyMT mice with palpable tumors
(8-weeks) were treated weekly with CX-5461 (50 or 87 mg/kg).
Consistent with an anti-proliferative impact22–24,49, significantly
smaller tumor volumes were detected with both doses of CX-5461
treatment over a 4-week time window (8–12 weeks) (Fig. 4d).
Histological examination of H&E-stained, CX-5461-treated pri-
mary tumors revealed a striking change of morphology indicative
of tumor regression and differentiation to a benign phenotype
(Fig. 4e). Confirming this interpretation, for both CX-5461
treatment regimens, the levels of the luminal epithelial differ-
entiation marker Cytokeratin 8/18 (CK8/18)50 increased and
returned to ductal areas, closely resembling the expression pattern
observed in pre-metastatic (6 weeks) primary tumors (Fig. 4e).
Elevated CK8/18 expression is associated with reduced cell
invasion and lung metastasis both in vitro and in vivo50.
Importantly, ERα expression also increased in CX-5461-treated
tumors (Fig. 4e), further confirming tumor differentiation to a
non-invasive, luminal phenotype51.
Corroborating our in vitro findings (Fig. 3a–c, e, f; Supple-
mentary Fig. 3c), and previous demonstrations that CX-5461
inhibits rRNA synthesis in vivo22–24,49, Snail1/2 levels were
reduced in the CX-5461-treated mice akin to the expression
pattern observed in pre-metastatic (6 weeks) primary tumors
Fig. 3 Inhibition of Pol I transcription initiation at rDNA operons impairs the EMT program. All cell culture experiments performed in NMuMG cells ±
TGFβ, ± CX-5461 treatments labeled in each panel. a Quantification of FUrd ± TGFβ and ± CX-5461; P < 0.003. b qRT-PCR of 45S (pre)-rRNA transcript ±
TGFβ ± CX-5461: Control vs. TGFβ, P < 0.05; TGFβ vs. TGFβ + CX-5461, P < 0.02. c Quantification of EdU ± TGFβ ± CX-5461, P < 0.002. d ChIP analysis of
UBF and Snail1 binding to the rDNA promoter ± TGFβ ± CX-5461: UBF, P < 0.027; Snail1, P < 0.018. e Immunostaining of Vimentin (green), Phalloidin (green)
and Snail1 (green) ± TGFβ ± CX-5461. f Quantification of Vimentin (Vim) and Snail1 immunofluorescence from e, P < 0.02. g Relative percent invasion from
Boyden chamber invasion assay ± TGFβ ± CX-5461, P < 0.002. h Immunostaining of Rictor (green), Calnexin (red), Rictor/Calnexin (white arrows, yellow)
and DAPI (blue) ± TGFβ ± CX-5461. i Immunostaining of Rictor (green) ± RNase A treatment. j qRT-PCR of Vimentin (Vim), Snail1 and Rictor mRNA
expression, P < 0.02. Asterisk denotes t-test significance. Error bars ± SE, n= 3. Scale bar for all images= 50 µm
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(Supplementary Fig. 4d). CX-5461 treatment did not affect
autophagy, as indicated by LC3 staining52 (Supplementary Fig.
4e). In line with mTORC2’s contribution to ribosome biogenesis-
associated tumor progression and dedifferentiation13,53, we also
observed a marked reduction in Rictor expression following CX-
5461 treatment (Fig. 4e; Supplementary Fig. 4b). Given that
Snail1 is positively regulated by mTORC245, and that
Snail1 suppresses CK8/18 and ERα expression during
EMT45,54,55, we conclude that CX-5461-mediated inhibition of
rRNA biogenesis in vivo induces tumor differentiation through
the disruption of an mTORC2/Snail1/ERα signaling axis.
Consistent with regression to a benign and less invasive
phenotype, both CX-5461 regimens reduced the size and number
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Fig. 4 Ribosome biogenesis inhibition reduces primary tumor growth and metastasis. a H&E staining of 6-, 8- and 12-week MMTV-PyMT mouse primary
tumor samples. Scale bar= 240 µm. b Immunostaining for Pol I (green) and Ki67 (green) merged with DAPI (blue) in MMTV-PyMT mouse tumors at 6-,
8- and 12-week. White arrows= tumor front. Scale bar= 50 µm. c IHC staining for Pol I and Ki67 in E0771 primary tumor and corresponding lung
metastasis. Scale bar= 240 µm. d Quantification of MMTV-PyMT primary tumors: vehicle (PBS), 50mg/kg, and 87mg/kg of CX-5461, ANOVA P < 0.01,
n= 4 vehicle, n= 3 per CX-5461 group. e H&E staining of MMTV-PyMT primary tumors: vehicle-treated, 50mg/kg or 87mg/kg CX-5461 as well as 6-
week pre-malignant tumors. IHC staining of Rictor, Cytokeratin 8/18 (CK8/18) and estrogen receptor alpha (ERα) expression in vehicle-treated, 50mg/kg,
or 87 mg/kg CX-5461 tumors or 6-week pre-malignant tumors. Scale bar= 50 µm. f H&E staining of metastatic lesions in CX-5461-treated and vehicle-
treated mice. Scale bar= 50 µm. Quantification of lung metastasis in CX-5461-treated and vehicle-treated mice, ANOVA P < 0.02. Error bars ± SD.
g Quantification of mCherry positive E0771 cells seeded and colonized in the lungs of vehicle and 50mg/kg CX-5461-treated C57BL/6 mice, t-test P <
0.01. Quantification of metastatic growth of mCherry positive E0771 cells in the lungs of vehicle and 50mg/kg CX-5461-treated C57BL/6 mice, t-test, P <
0.05. n= 3 vehicle, n= 4 CX-5461 treatment. All asterisks denote significance
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of rRNA synthesis by CX-5461, in addition to its antiproliferative
effects, can act to induce tumor differentiation and reduce
metastasis in vivo.
Ribosome biogenesis inhibition reduces metastatic seeding. To
test whether rRNA synthesis contributes to metastasis in the
absence of a primary tumor, metastatic seeding and lung colo-
nization were examined using the syngenic, basal-like, E0771
metastasis mouse model48. To do so, C57BL/6 mice were either
treated with vehicle or pre-treated with CX-5461 (50 mg/kg) 24 h
prior to tail vein injection of mCherry-labeled E0771 cells. Tumor
cell injections were then followed by CX-5461 dosing (50 mg/kg)
twice per week over a 5-week period. In mice pre-treated with
CX-5461, injected tumor cells were less capable of seeding and
colonization in the lung (Fig. 4g). Lung metastasis colonization
was also significantly decreased when E0771 cells were tail vein
injected into mice that were subsequently dosed with CX-5461
(50 mg/kg) 24 h post injection, followed by 2 weeks bi-weekly
CX-5461 dosing (50 mg/kg) (Fig. 4g). These data indicate that
CX-5461-mediated inhibition of rRNA synthesis in vivo attenu-
ates pro-invasive programs, limiting metastasis through the
inhibition of seeding and metastatic tumor growth.
Pol I expression correlates with dedifferentiation. To assess the
clinical relevance of our findings, we examined Pol I in normal
human breast tissue and in invasive breast tumors. Invasive
tumors exhibited significantly higher levels of Pol I staining
compared to normal tissues (Fig. 5a). Pol I expression was also
more highly expressed in aggressive, dedifferentiated basal-like
triple negative breast cancers (TNBC) compared to less aggressive
differentiated, luminal ERα+ tumors (Fig. 5b). Notably, high Pol I
and UBF expression correlates with a reduced probability of
relapse-free survival (Fig. 5c). While further experiments are
required to delineate the relative contributions of Pol I expression
in these systems to proliferation versus EMT, the evidence pre-
sented suggests that the EMT-associated ribosome biogenesis
program contribute to dedifferentiation and human breast cancer
progression.
Discussion
rDNA transcription, the initiating step in ribosome biogenesis, is
canonically associated with an elevation of protein synthesis to
accommodate growth and cell division18,19,29,35. Unexpectedly,
we show that the EMT program, a cell identity switch critical to
development, wound healing, and disease5 is accompanied by
transcriptional activation of rDNA operons that are normally
silenced, or partially silenced, in the epithelial state. Notably, we
find that this feature of EMT is independent of initiating stimulus
and species. Interestingly, the EMT-associated ribosome biogen-
esis occurs when cells are arrested at the G1/S transition, the
“restriction point” prior to the commitment to cell division38.
These changes may be mediated, at least in part, by increased
nuclear Snail1 levels, which transcriptionally represses cyclin D1
expression via direct binding to its promoter region7.
During G1/S arrest, we observe that global levels of protein
synthesis are modestly reduced compared to proliferating cells,
while specific mesenchymal markers that contribute to the cel-
lular capacity to migrate and invade distal tissues are increased.
Consistent with this notion, our pharmacological and RNAi-
mediated inhibition studies argue that ribosome biogenesis dur-
ing EMT fuels a gene expression program that is required to
achieve the mesenchymal cell state. Our investigations of chick
and mouse development show that rRNA synthesis levels are
highest in delaminating neural crest cells, where defects in ribo-
some biogenesis have been associated with severe developmental
malformations56,57. Roles for ribosome biogenesis and transla-
tional control have also been evidenced in congenital mal-
formations linked to neural crest development56,57. These
findings collectively argue that ribosome biogenesis during cell
cycle arrest is a general feature of the EMT program.
Stem cells are permissive to differentiation signals, including
TGFβ, during the G1 phase of the cell cycle58. Differentiation
towards the three embryonic germ layers is canonically linked to
heterochromatin decompaction in preparation for DNA replica-
tion and the induction of distinct Pol II-driven transcriptional
programs58. The present investigations suggest that Pol I activities
are also regulated during the cell cycle, and cell cycle arrest at the
G1/S transition in particular.
A distinguishing feature of the ribosome biogenesis program
evidenced during EMT is its significant elevation relative to that
which is observed in the G1 phase of normally cycling cells. The
EMT-associated ribosome biogenesis program is also dis-
tinguished by a marked increase in Snail1 binding to rDNA
operons concomitant with release of the repressive NoRC.
Notably, increased Snail1 expression alone is sufficient to induce
rRNA synthesis in the absence of TGFβ. Reciprocal
Snail1 silencing studies during TGFβ-induced EMT, while
potentially informative to understanding Snail1-independent
aspects of TGFβ signaling, were not considered here due to
Snail1’s central role in a multitude of distinct aspects of the EMT
program, potentially including cell cycle arrest. Snail’s active
participation in the EMT-associated ribosome biogenesis pro-
gram extends its pervasive Pol II regulatory capacities3 to the Pol
I machinery, putting it in a similar class as the Myc oncogene as a
pan-RNA polymerase regulator59.
The distinct nature of the EMT-associated ribosome biogenesis
program is further evidenced by the increase in Rictor expression
at the point of G1/S arrest and its localization to nucleoli. In
proliferating cells, Rictor expression is normally enhanced during
S phase60 and its localization is primarily cytoplasmic, where it
associates with mitochondria-associated endoplasmic reticulum
membranes (MAMs)61. mTORC2’s contributions to the
mesenchymal gene expression program and its activation upon
ribosome association are well established13,14,45. We speculate
that the EMT-associated ribosome biogenesis program, driven by
Snail1-directed changes in rDNA transcription, directs Rictor’s
association with newly generated ribosomes. In so doing, the
EMT-associated ribosome biogenesis program may template
mTORC2’s assembly with ribosomes to thereby promote its
activation and subsequent regulation of gene expression (Fig. 5e).
In support of this “ribo-interactome” model62,63, CX-5461-
mediated inhibition of ribosome biogenesis during EMT redu-
ces Snail1’s association with rDNA, abrogates Rictor’s nucleolar
and MAM localization, and hampers the expression of mTORC2-
regulated mesenchymal markers. At the same time, Smad4
localization remains intact, suggesting a Smad4-independent
mechanism of Rictor association with ribosomes and mTORC2
activation. We note in this context that EMT can also be blocked
by the inhibition of ribosome export from the nucleus64. Further
experiments will be required to validate these mechanistic con-
nections, including focused investigations into the activation
status of downstream mTORC2 signaling cascades. Additional
studies will also be needed to delineate the specific signaling
pathways contributing to activation of the EMT-associated ribo-
some biogenesis program in different physiological contexts.
Cells arrested in G1/S during EMT are significantly larger than
those that are cycling normally65. The induction of ribosome
biogenesis during EMT may, therefore, reflect homeostatic
mechanisms that scale ribosome concentration in relation to
changes in cell size17,66. Ribosome biogenesis may, however, also
play a more active role in facilitating execution of the EMT
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program by influencing gene expression and thus cell fate. For
instance, the induction of rRNA expression may increase the
number of active ribosomes to elicit gene-specific impacts on
translation efficiency, including increased protein production
from transcripts containing long, structured 5′-untranslated
regions67. Changes in ribosome abundance may also perturb the
translation efficiencies of specific genes by altering the availability
of protein synthesis components or other complexes, such as
mTORC2, that mediate cellular signaling cascades through
association with the ribosome13,14. Primary rRNA transcripts and
intermediates of ribosome assembly may also sequester cellular
factors to indirectly influence protein synthesis68,69. Mechanisms
wherein newly synthesized ribosomes exhibit physical and func-
tional distinctions, which give rise to gene-specific translational
control, can also be envisaged39,62. In this context, it will be
critical to determine whether the EMT-associated ribosome bio-
genesis program activates all rDNA operons equally or if there are
physiological alterations in the relative expression of specific
rDNA operons, as has been observed in other systems39,70,71.
Distinguishing whether the EMT-associated ribosome biogenesis
program reflects the upregulation of specific classes of rDNA
operons normally silenced in the differentiated state, and if the
upregulation of ribosome biogenesis is a causal feature of the
mesenchymal gene expression program, will require deeper
knowledge of the full repertoire of rDNA operon sequences
encoded by mammalian cells. Detailed investigations of the
ribosome pool and the specific translation programs prior and
subsequent to EMT may also aid examinations of the relationship
between the EMT-associated ribosome biogenesis program and
the accompanying changes in gene expression and cell fate.
The importance of such pursuits is highlighted by the pre-
clinical studies presented, which reveal that pharmacological
inhibition of rRNA synthesis slows primary tumor growth and
differentiates tumors in a manner that reduces metastatic seeding
and growth (Fig. 5e). Such changes were found to stem, at least in
part, from reductions in Rictor and Snail1/2 protein levels. We
infer from these findings that programmed changes in the
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Fig. 5 Human breast tumors exhibit high-levels of Pol I expression. a IHC staining of Pol I in normal human breast tissue and invasive breast tumor tissue.
b IHC staining of Pol I in TNBC and ERα+ tumors. Pol I intensity scoring TNBC compared to ERα+ tumors, t-test, P < 0.01. Error bars ± SD. Asterisk denotes
significance. Scale bar= 240 µm. c Survival curve showing induced expression of Pol I and UBF correlates with lower relapse-free survival in patients with
breast cancer, P < 0.006. d Schematic model showing TGFβ-induced, G1/S arrest of the cell cycle during EMT, accompanied by association of Snail1, Pol I
and UBF with rDNA operons, TIP5 dissociation, and the generation of new Rictor-associated ribosomes. e Model depicting reduced primary tumor growth
and metastasis via CX-5461-mediated inhibition of rRNA synthesis
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the EMT-associated ribosome biogenesis program, influence the
process of colonization at new tumor growth sites (Fig. 5e).
In this context, it is particularly striking that CX-5461 can
induce solid tumor differentiation from a basal-like to a luminal
ERα+ phenotype. This finding suggests that CX-5461 may have
the potential to restore or enhance endocrine therapy respon-
siveness in ERα- or endocrine-resistant patients, whose tumors
are typically more dedifferentiated, aggressive and prone to
reoccurrance and metastasis72,73. The capacity of CX-5461 to
mediate such impacts represents a rare demonstration that a
small-molecule can induce differentiation in solid tumors, which
may also afford potential synergies with anti-proliferative thera-
pies. These possibilities motivate focused assessments of the
precise mechanisms by which rRNA synthesis influences tumor
plasticity, metastatic spread and secondary tumor growth,
wherein mesenchymal cells renew their proliferative capacity3.
Initiatives of this kind must include in-depth explorations of CX-
5461’s specific molecular target(s) in the cell, the mechanistic
basis of it’s actions and how, specifically, CX-5461-mediated
inhibition of rRNA synthesis during EMT regulates the
mesenchymal gene expression program. Given the findings pre-
sented, such efforts may have the potential to offer new avenues
for differentiation therapies74 and to inform on new strategies to
treat aggressive, metastatic cancers for which current approaches
are inadequate.
Methods
Cell culture and reagents. Namru Mus musculus mammary gland (NMuMG)
cells acquired from ATCC and NMuMG-Snail1-ERT2 (gift from Dr. Nieto) were
maintained in Dulbecco’s Modified Eagle Medium (DMEM, Gibco/Invitrogen),
10% fetal bovine serum (FBS, Gibco/Invitrogen), GlutaMAX (Gibco #35050),
penicillin–streptomycin (PenStrep, Gibco #15140122) and insulin 10 µg/mL (Sig-
ma#I0516). Michigan Cancer Foundation-7 (MCF7) cells were a gift from Dr.
Jonas Fuxe, Karolinska Institute, and Py2T cells were a gift from Prof. Gerhard
Christofori, University of Basel. Both were grown in DMEM with 10% FBS, Glu-
taMAX and PenStrep. The NMuMG-Fucci2 cells (RCB2868) were obtained
from the RIKEN BRC through the National Bio-Resource Project of the MEXT,
Japan and Dr. Atsushi Miyawaki.
Recombinant human TGFβ1 protein (R&;D, #240B) was added to 10 ng/mL to
induce EMT. Snail1 was induced in NMuMG-Snail1-ERT2 cells by the addition of
4-hydroxytamoxifen at 200 nM for 72 h. CX-5461 (Cylene Pharmaceuticals, San
Diego, USA, Selleckchem, San Diego, USA) was added to a final concentration of
100 nM, actinomycin D (A1410, Sigma) was added to a final concentration of 0.01
μg/mL and aphidicolin (A0781, Sigma) to a final concentration of 10 µM. For
hypoxia, cells were transferred to a hypoxia chamber (1% oxygen) for 48 h prior to
analysis. FUrd and EdU chases were performed post-hypoxia under normal
culturing conditions. All cell lines were routinely checked for mycoplasma
contamination.
Immunostaining. Cells were plated on glass cover slips at 20% confluency one day
prior to treatment with TGFβ (or vehicle). CX-5461 (100 nM), actinomycin D
(0.01 μg/mL), or aphidicolin (10 μM) were added 27 h post TGFβ treatment for an
additional 24 h. After treatment, depending on the intended primary antibody, cells
were fixed with 4% paraformaldehyde, ice-cold ethanol or ice-cold methanol
(Supplementary Table 1). Formaldehyde fixation continued for 15 min, followed by
permeabilization with 0.3% Triton X-100 in PBS for 15 min and 1 h of blocking
with 1% BSA in PBS with 0.3% Triton X-100. Methanol fixation was limited to 20 s
and ethanol fixation to 10 min at room temperature. Post ethanol fixation cells
were permeabilized for 5 min with 0.1% Triton X-100 in PBS, and samples fixed by
both methanol and ethanol were blocked for 1 h with 1% BSA-PBS. See Supple-
mentary Table 1 for antibody details. With formaldehyde fixation, after blocking,
cells were stained overnight at 4 °C with primary antibodies diluted in 1% BSA in
PBS with 0.3% Triton X-100. The following day, cells were incubated for 1 h with
secondary antibodies diluted 1:1000 in 1% BSA in PBST. Cells were washed three
times with PBST after antibody incubation. The same antibody incubation and
washing procedures were followed for cells fixed with methanol or ethanol, how-
ever Triton X-100 was omitted in the wash and antibody incubation steps. For both
phalloidin staining and processing of 5-ethynyl-2′-deoxyuridine (EdU) pulsed cells
with azide-Click-IT technology, manufacturer’s protocols were followed. Secondary
antibodies included Alexa Fluor 647 goat anti-mouse and Alexa Fluor 647 goat
anti-rabbit (A21233 and A21244, Invitrogen). Following secondary antibody
staining, phalloidin or EdU protocols, cells were washed three times with PBS and
stained with DAPI diluted in PBS and mounted on cover slips. Cover slips were
visualized using Leica and Zeiss LSM 710 confocal microscopes. Each experiment
was performed on 3 biological replicates.
RNase A treatment protocol. Pre-fixation: Proliferating and TGFβ-treated cells
were washed twice with PBS for 3 min before treatment with 2 mg/mL RNase A in
PBS for 15 min at room temperature. Cells were fixed with 4% paraformaldehyde
in PBS for 15 min at room temperature before proceeding to immunofluorescence
staining. Post-fixation: Proliferating and TGFβ-treated cells were washed twice with
PBS for 3 min and were fixed with 4% paraformaldehyde in PBS for 15 min at
room temperature. The cells were washed twice with PBS for 3 min before treated
with 2 mg/mL RNase A in PBS for 15 min at room temperature. The cells were
washed twice with PBS before proceeding to immunofluorescence staining. Each
experiment was performed on 3 biological replicates.
Cell count. 70,000 NMuMG cells were seeded per well of a 6-well plate. Both
proliferating and TGFβ-treated cells were trypsinized after 48 h and counted using
the NucleoCounter® NC-3000™. Experiment was performed on 3 biological repli-
cates, error bars are the mean ± SD and the two-tailed Students t-test, P < 0.001
(Supplementary Fig. 1f).
Brightfield microscopy. Unfixed cells were imaged using a Zeiss Axiovert 40 CFL
microscope using an AxioCam ICm1 camera and Axiovert software.
Quantifications of immunostaining. Fluorescent signal intensity was quantified
using ImageJ software. Images were converted to 8-bit depth, thresholded and
signal intensity was quantified by measurement of ‘Integrated Density’ taking into
account both signal intensity and area of signal expression. Threshold values were
consistent across all treatment conditions for a given marker. The resulting
‘Integrated Density’ value was then divided by the number of cells in the field as
identified through DAPI staining. The treatment values are relative to the value of
the control condition, which was set to a value of one (1). For EdU and Ki67, the
number of EdU+ or Ki67+ cells were counted, and this number was then divided
by the total number of cells in the field, identified by DAPI staining, and converted
to a percentage value. Colocalization of FUrd and EdU was determined by mea-
surement as the percentage of FUrd signal that was in EdU positive cells out of
total FUrd signal per 100 cells per condition, and graphs shown represents how
much of that signal was localized to EdU+ cells.
Statistics for quantification of immunostaining. For all quantification, asterisks
denote significance as assessed with two-tailed Student’s t-test. In figure legends,
the highest P-value is shown.
Statistics for Figure 1 data. Quantification of FUrd incorporation in NMuMG
cells calculated as average signal intensity per cell, P < 0.01 (Fig. 1b). Quantification
of EdU positive cells out of a total number of DAPI-positive cells in NMuMG cells,
P < 0.001 (Fig. 1b). Quantification of AHA incorporation in NMuMG cells calcu-
lated as average signal intensity per cell, P < 0.0005 (Fig. 1b). Quantifications of
average FUrd signal intensity and of percentage EdU positive cells out of a total
number of DAPI-positive cells with and without TGFβ treatment in Py2T cells, P <
0.04 (EdU and FUrd) (Fig. 1c). Quantifications of average FUrd signal intensity
and percentage EdU positive cells out of a total number of DAPI-positive cells with
and without hypoxia-induced EMT in MCF7 cells, P < 0.05 (EdU), P < 0.001
(FUrd) (Fig. 1d). Quantification of signal during time course ± mean standard
error: FUrd control 27 h (0.04), 48 h (0.08) and 96 h (0.05); TGFβ-treated 27 h
(0.06), 48 h (0.15) and 96 h (0.26); EdU control 27 h (0.007), 48 h (0.01) and 96 h
(0.01); TGFβ-treated 27 h (0.14), 48 h (0.05) and 96 h (0.14) (Fig. 1i, j). Assessment
of time course via Student’s t-test: FUrd, control compared to TGFβ (27, 48 and
96 h) and control (96 h) compared to control (48 and 27 h), P < 0.01; EdU: control
(27 h) compared to control (48 and 96 h), and control compared to TGFβ (27, 48
and 96 h), P < 0.02 (Fig. 1i, j).
Statistics for Supplementary Figure 1 data. Quantification of Ki67 positive cells
out of a total number of DAPI positive cells in NMuMG cells, P < 0.001 (Sup-
plementary Fig. 1e). Quantification of localization of FUrd signal to EdU positive
cells with and without TGFβ treatment, P < 0.001 (Supplementary Fig. 1h).
Quantification of time course (Fig. 1i; Supplementary Fig. 1n), Vimentin and E-
cadherin at 27, 48 and 96 h in control and TGFβ treated NMuMG cells. E-cadherin:
control compared to TGFβ (48 and 96 h), P < 0.002; between TGFβ time points,
P < 0.05. Vimentin: control compared to TGFβ (27, 48 and 96 h), P < 0.02; control
(48 h) compared to control (96 h) and for all comparisons of TGFβ conditions, P <
0.02.
Statistics for Figure 2 data. Quantification of EU incorporation in NMuMG cells
calculated as average signal intensity, P < 0.0002 (Fig. 2l).
Statistics for Figure 3 data. Quantification of average FUrd signal intensity per
cell and percentage of EdU+ cells in control, CX-5461, TGFβ, and TGFβ+CX-5461
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treated NMuMG cells (Fig. 3a, c). FUrd: P < 0.003 control compared to TGFβ, and
TGFβ compared to TGFβ+CX-5461. EdU; P < 0.002, control compared to TGFβ,
and control compared to control+CX-5461. Quantification of Vimentin and Snail1
immunofluorescence intensity in control, CX-5461-treated, TGFβ and TGFβ+CX-
5461-treated NMuMG cells (Fig. 3f). Vimentin: control compared to TGFβ and
TGFβ compared to TGFβ+CX-5461, P < 0.001. Snail1: control compared to TGFβ
and TGFβ compared to TGFβ+CX-5461, P < 0.002; control compared to CX-5461,
P < 0.02.
Statistics for Supplementary Figure 3 data. Quantification of p53 immuno-
fluorescence intensity in control, CX-5461-treated, TGFβ-and TGFβ+ CX-5461-
treated NMuMG cells, P < 0.001 (Supplementary Fig. 3a). Quantification of UBF
immunofluorescence intensity in control, CX-5461-treated, TGFβ- and TGFβ+
CX-5461-treated NMuMG cells, P < 0.001 (Supplementary Fig. 3b). Quantification
of average FUrd signal intensity per cell and percentage of EdU+ cells in control,
actinomycin D-, TGFβ- and TGFβ+ actinomycin D-treated NMuMG cells (Sup-
plementary Fig. 3g). FUrd: control compared to control+ actinomycin D, P < 0.02;
control compared to TGFβ, and TGFβ compared to TGFβ+ actinomycin D, P <
0.001. EdU: control compared to actinomycin D and control compared to TGFβ,
P < 0.001. Quantification of Vimentin and Snail1 immunofluorescence intensity in
control, actinomycin D-treated, TGFβ- and TGFβ+ actinomycin D-treated
NMuMG cells (Supplementary Fig. 3g). Vimentin: control compared to actino-
mycin D, P < 0.01; control compared to TGFβ, P < 0.01. Snail1: control compared
to TGFβ and TGFβ compared to TGFβ+ actinomycin D, P < 0.002 (Supplemen-
tary Fig. 3h). Quantification of percentage of EdU+ cells in control, aphidicolin-,
TGFβ- and TGFβ+ aphidicolin-treated NMuMG cells, P < 0.001(Supplementary
Fig. 3c). Quantification of average Pol I, EU and Vimentin signal intensity per cell
in ctrl siRNA and Pol1 siRNA treated NMuMG cells, P < 0.0002 (Supplementary
Fig. 3i). Quantification of average FUrd signal intensity per cell, aphidicolin-,
TGFβ- and TGFβ+ aphidicolin-treated NMuMG cells. FUrd: control compared to
TGFβ, P < 0.002 (Supplementary Fig. 3c). Quantification of Snail1 immuno-
fluorescence intensity in control-, aphidicolin-, TGFβ- and TGFβ+ aphidicolin-
treated NMuMG cells, P < 0.01 (Supplementary Fig. 3c). Quantification of Rictor
immunofluorescence intensity in control, CX-5461-treated, TGFβ- and TGFβ+
CX-5461-treated NMuMG cells. Rictor: control compared to TGFβ and TGFβ
compared to TGFβ+ CX-5461, P < 0.0001; control compared to CX-5461, P <
0.0001 (Supplementary Fig. 3m). Quantification of Smad4 immunofluorescence
intensity in control, CX-5461-treated, TGFβ- and TGFβ+ CX-5461-treated treated
NMuMG cells, P < 0.001 (Supplementary Fig. 3n)
Western blotting. Cells were lysed and sonicated in RIPA buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS) supplemented with protease inhibitors (cOmplete cocktail EDTA-free,
Roche). Protein extracts were boiled in sample buffer (BioRad), separated by
SDS–PAGE under reducing conditions and transferred to nitrocellulose filters
(BioRad) by semi-dry electro-blotting. Nuclear fractions for TIP5 were obtained
using NE-PER cell fractionation kit (Thermo Scientific, #78833). Primary anti-
bodies are listed in Supplementary Table 1. Immunoreactive bands were visualized
by chemi-luminescence (BioRad) and a BioRad ChemiDoc XRS imaging system.
Each experiment was performed on 3 biological replicates.
rRNA, DNA, and nascent peptide synthesis in vitro. FUrd assay was performed
as previously described28,29. Cells were pulsed with 2 mM FUrd for 8–10 min
following 48 h of treatment (TGFβ or hypoxia), under normal culturing conditions.
Following the pulse, cells were rinsed with PBS and fixed with paraformaldehyde.
In addition, cells were pulsed with 20 μM EdU for 45 min according to manu-
facturer instructions under normal culturing conditions, following the pulse cells
were rinsed with PBS and fixed with paraformaldehyde. Click-it assay was per-
formed as specified by manufacturer instructions. Briefly, cells grown in
methionine-free media were pulsed with the AHA amino acid analog for 30 min.
Cells were fixed with paraformaldehyde for 15 min, permeabilized with 0.3%
triton-PBS for 15 min and then the incorporated analogs were labeled via Click-it
chemistry using the Alexa Fluor 488 azide. Cells were then washed with PBS,
stained with DAPI and mounted. Each experiment was performed on 3 biological
replicates. Significance was assessed with two-tailed Student’s t-test.
qRT-PCR analysis. For semi-quantitative analysis, total RNA was extracted fol-
lowing the manufacturer’s protocols (Qiagen RNeasy mini kit, Qiagen). cDNA was
synthetized using a high-capacity RT-kit (Applied Biosystems). Primer sets for
these experiments are listed in Supplementary Table 2. Expression levels were
determined using SYBR-green mix (Applied Biosystems) and a real-time ther-
mocycler (Applied Biosystems 7500). qRT-PCR values were calculated relative to
Gapdh1. Each experiment was performed on 3 biological replicates. Significance
was assessed with two-tailed Student’s t-test. Statistics: Supplementary Fig. 1c, P <
0.02; Fig. 2a, P < 0.015; Supplementary Fig. 2d, P < 0.01; Fig. 2g, Polr1a, Sirt7,
Rrn3, Fbl and Ncl, P < 0.01; Fig. 3c, P < 0.05; Fig. 3j, P < 0.02; Supplementary Fig.
3b, P < 0.02.
siRNA experiments. 6 × 104 cells were seeded in a 6-well plate and on the fol-
lowing day treated with 50 nM of ON-TARGET plus Polr1a siRNA- SMARTpool
(Dharmacon) and ON-TARGET plus Non-targeting pool (Dharmacon) respec-
tively using DharmaFECT 4 (Dharmacon) transfection reagent overnight. Media
was replaced the next day and the cells are treated with TGFβ on the 4th day. The
cells were fixed with 4% paraformaldehyde after 48 h and subsequently stained for
the respective markers.
Northern blot analysis. Total RNA from NMuMG cells treated with or without
TGFβ was prepared using Tri reagents (Ambion) and loaded on a 1.5% agarose-gel
containing 6.5% formaldehyde. Equal amount of RNA was transferred to a
nitrocellulose membrane which was probed with radioactively labeled ETS-1 oli-
gonucleotide ETS-5’-agctccccacgggaaagcaatgagtctctc. The oligonucleotide was end-
labeled using T4-kinase and P-32 gamma-ATP. Quantifications of Northern blots
were conducted using Fuji Phosphoimager. Experiment was performed on 3 bio-
logical replicates. Significance was assessed with two-tailed Student’s t-test: Sup-
plementary Fig. 2b P < 0.028; Supplementary Fig. 2c, P < 0.035.
AgNOR staining. Silver staining of NORs in control cells and TGFβ-treated cells
was performed using previously described AgNOR procedures75. Briefly, after
fixation, incubation with Carnoy’s Solution and rehydration, cells were stained with
a freshly prepared AgNOR staining solution for 30 min. After staining, cells were
rinsed twice in distilled water, treated with 5% sodium thiosulfate for 2–5 min,
rinsed again, and mounted for brightfield microscopy using a Nikon E600 Camera
and image capture. Each experiment was performed on 3 biological replicates.
Chromatin immunoprecipitation. ChIP assays were performed as previously
described28,29. Formaldehyde cross-linked chromatin obtained from control or
TGFβ-treated NMuMG cells were subjected to immunoprecipitation with the
autoimmune serum S57299 against Pol I or with antibodies to UBF, SIRT7, Snail1,
TIP5, and non-specific mouse IgG as a control (see Supplementary Table 1 for
antibody details). DNA-protein complexes were analyzed by qRT-PCR with primers
specific for the rDNA promoter, 28 S and 18 S gene in addition to the Snail1 and E-
cadherin promoters (primers listed in Supplementary Table 2). The qRT-PCR
analysis was performed as previously described. Results are displayed as bars graphs.
All ChIP data are presented as a fold induction over IgG control and as relative
occupancy. Each experiment was performed on 3 biological replicates. Significance
was assessed with two-tailed Student’s t-test. Statistics: Fig. 2f, P < 0.03; h P < 0.006
and P < 0.005; i P < 0.015 and P < 0.04; j P < 0.005; k P < 0.03; Supplementary
Fig. 2l, P < 0.0002; Fig. 3d, UBF: control compared to TGFβ, P < 0.007; control
compared to control+ CX-5461, P < 0.027; TGFβ compared to TGFβ+ CX-5461,
P < 0.003. Snail1: control compared to TGFβ, P < 0.003; control compared to
control+ CX-5461, NS; TGFβ compared to TGFβ+ CX-5461, P < 0.02.
HpaII-methylation assay. NMuMG cells treated with or without TGFβ for 48 h
were cross-linked with 1% formaldehyde and chromatin was isolated. The chro-
matin was sonicated 10 times for 30 s. Cross-linked DNA was purified with phenol/
chloroform and precipitated with ethanol. Purified DNA was digested with
methylation-sensitive HpaII and MspI separately. DNA was amplified by qRT-PCR
using rDNA promoter primers and the ratio between HpaII and Msp I was cal-
culated. Upon methylation, cleavage with HpaII is blocked, while MspI remain
unaffected and subsequently induced ratio represent loss of methylation. Each
experiment was performed on 3 biological replicates. Significance was assessed with
two-tailed Student’s t-test. Control compared to TGFβ, P < 0.007 (Fig. 2g).
Invasion assays. The invasive properties of the NMuMG were measured using a
Matrigel invasion assay. Cell culture plate inserts (24-well inserts, 0.8-µm pore size;
BD Bioscience, Bedford, MA, USA) were coated with Matrigel (1 mg/ml; BD
Bioscience). All cells were pre-incubated in media with or without TGFβ for 48 h
and 100 nM CX-5461 or 0.01 μg/mL actinomycin D were added at 27 h of TGFβ
treatment. Medium with 10% FBS containing 1 × 104 cells were added to the upper
chamber insert, and 500 µl of DMEM with 10% FBS was added to the lower
chamber. The cells were incubated for 24 h at 37 °C in 5% CO2 humidified incu-
bator. Cells that did not pass through the Matrigel were removed from the insert
with a cotton swab; invasive cells that crossed the membrane were fixed in 4%
paraformaldehyde and subsequently stained with DAPI. The membrane of the
insert was cut out and fixed onto a slide with fluorescent mounting medium. The
representative number of invasive cells was evaluated by imaging using the Zeiss
Confocal microscope and counting invading cells in 10 fields per condition. Each
experiment was performed on 3 biological replicates. Significance was assessed with
two-tailed Student’s t-test. Statistics: Fig. 3g: control compared to TGFβ, P < 0.002
TGFβ compared to TGFβ+ CX-5461, P < 0.001; Supplementary Fig. 3f: control
compared to control+ActD, P < 0.003; control compared to TGFβ+ActD, P <
0.001; Supplementary Fig. 3j, P < 0.001.
Gene expression profiling. NMuMG cells were cultured and treated with TGFβ
and CX-5461 as described above. Ribosome profiling was performed as previously
described76, with the following changes: ribosomes were pelleted through a 1M
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sucrose cushion containing 20 mM Mg2+, 500 mM NH4Cl, 500 mM cyclohex-
imide. Ribosome pellets were resuspended and subunits were dissociated in buffer
containing 500 mM KCl, 2 mM puromycin in PBS (pH 7.4), and SUPERase*In™
RNase inhibitor (Thermo; final concentration of 100 U/mL buffer). Ribosomal
subunits were pelleted at 438k*g in a TLA 100.3 rotor for 2 h at 4 °C and the
supernatant containing ribosome protected fragments was collected and processed
for RNA sequencing. Subtractive depletion of rRNA was not performed during
library preparation. RNA sequencing was performed on an Illumina HiSeq 2500
instrument at the Genomics Resources Core Facility of Weill Cornell Medicine.
Adapter clipping and basic quality filtering were performed on raw sequencing
reads using the Fastx toolkit. Reads were then aligned with STAR77 to the mouse
reference genome GRCm38 from Ensembl78. Relative expression levels were cal-
culated using RSEM6 and Limma-voom79 was applied to determine differential
expression (DE) based on the total number of ribosome protected fragments that
mapped to annotated mRNAs. We employed a false discovery rate (FDR) threshold
of 5%. All RNA sequencing data have been deposited to the Sequence Read Archive
under BioProject PRJNA531030. Enrichment of gene ontology categories was
determined as previously described44.
Chick developmental experiments. Fertilized chicken eggs were incubated at
37 °C until Hamburger and Hamilton stage 18/19. A small window was made in
the eggshell, followed by a hole in the upper membrane through which 200 µL of
200 mM FUrd or 50 mM EdU was injected. Eggs were resealed with tape and
incubated at 37 °C for 1 h. Embryos were fixed in 4% paraformaldehyde (PFA) for
1 h at room temperature, washed in PBS then incubated overnight in 30% sucrose
and subsequently frozen down in Tissue-Tek O.C.T. (Sakura) for sectioning. Sec-
tions were washed in PBS and stained overnight at 4 °C for FUrd and Snail1/2, see
(Supplementary Table 1) for antibody details. Secondary antibodies listed pre-
viously were applied at 1:1000 dilution for 45 min, followed by DAPI stain. EdU
detection was achieved using Click-IT azide-Alexa Fluor 488 (Life Technologies)
according to the manufacturer’s protocol. All images were captured with a Zeiss
Confocal microscope. Chick experiments were repeated at least 3 times with 2 or
more embryos.
Mice developmental experiments. Pregnant mice were injected intraperitoneally
at embryonic day E9.0 with 200 uL PBS containing 2 mg BrdU (Thermofisher,
B23151) and 2 mg EU (Thermofisher, E10345). 4 h later mice were sacrificed with
isufolran and harvested embryos were fixed for 2 h in 4% PFA at 4 degrees. After
overnight incubation in 30% sucrose embryos were embedded in OCT (HistoLab,
45830) and transversally cut in cryosections at 16 µM. Sections were either stored at
−20 °C or processed immediately after sectioning. Before primary antibody incu-
bation, sections were treated with DAKO Target Retrieval Solution (Agilent
S169984-2) according to the manufacturer’s instructions. Sectioned tissues were
incubated with primary Sox10 (Novusbio AF2864) antibody at a dilution of 1:500
overnight at RT in PBS-T (0,1% Tween). For detection of Sox10 488 conjugated
Alexa-Fluor secondary antibody produced in donkey (Thermofisher, A-11055
1:1000) was used in combination with secondary BrdU 405 (Novusbio, NBP2-
34784AF405 1:1000) for 3 h at RT diluted in PBS-T. Subsequently, to detect cells
that incorporated EU, Click-iT Alexa Fluor 647 Azide (Thermofisher, A10277) was
used according to the manufacturer’s instructions. All animal experimentation was
performed in accordance with institutional guidelines as detailed in animal pro-
tocol #1184203.
Animal studies and in vivo treatments. The genetically engineered mouse
MMTV-PyMT constitutes a faithful model for invasive and metastatic breast
carcinoma59. Tumors in MMTV- PyMT mice develop through a multistep path-
way due to oncogenic activation and end-stage mice present with locally invasive
tumors and disseminated disease to lymph nodes and lungs. To investigate the
therapeutic utility of inhibition of RNA polymerase I (Pol I) assembly, 8-weeks-old
MMTV-PyMT mice were treated once weekly with intraperitoneal injections of
CX-5461 at a 50 mg/kg (n= 3) and 87 mg/kg (n= 3), or vehicle (n= 4). Each week
before injections tumors were measured. Tumor volume measurements in Fig. 4d,
statistically evaluated with ANOVA, P < 0.01. At the conclusion of the experiment,
following 4 weeks of therapy, mice were sacrificed and primary tumors from all 10
mammary fat pads were harvested. Lungs were also harvested for assessment of
metastatic dissemination in Fig. 4f, statistically evaluated with ANOVA, P < 0.02.
To investigate the inhibitory effect on lung metastasis of E0771 cells by CX-5461,
C57BL/6 mice were separated into two groups, one with first treatment 24 h prior
and the other 24 h after the tail vein injection of 5 × 104 E0771 cells followed by
twice-weekly intraperitoneal injections of CX-5461 at 50 mg/kg in 50 mM sodium
phosphate buffer, pH 4.5. Control group was injected with corresponding amount
of buffer by mice weight. Mice were sacrificed after two weeks (post-treatment
group) or five weeks (pre-treatment group) after the tail vein injection. The number
of animals are (for both experiment) n= 3 for buffer control, n= 4 for CX-5461
treatment. Lungs were harvested for assessment of metastasis by mCherry
expression using qRT-PCR relative to β-actin expression. Primers are listed in
Supplementary Table 2 (Table S2). Statistics evaluated with two-tailed Students
t-test (Fig. 4g, P < 0.01; P < 0.05).
Mouse and human tissue evaluation. Primary tumors and corresponding lungs
from MMTV-PyMT mice at 6-weeks, 8-weeks or 12-weeks old, treated MMTV-
PyMT mice (vehicle, 50 mg/kg and 87 mg/kg doses of CX-5461) and E0771
mammary fat pad implanted mice were embedded in paraffin. E0771 cells (1 × 106)
were injected in mammary fat pad of C57BL/6 mice and primary tumor and lungs
were harvested at week three after injection. Primary tumors and lungs were sec-
tioned at 5 µm, de-paraffinized and stained according to standard protocols. H&E
was performed on MMTV-PyMT mice at 6-weeks, 8-weeks or 12-weeks old,
treated MMTV-PyMT mice to determine tumor morphology. Early metastatic
lesions were identified in lungs of 8-weeks old mice with IHC for PyMT antigen.
IHC for identification of expression levels of Pol I (autoimmune serum S57299
against Pol I) and Ki67 (experiments performed in at least 2 or more mice) was
performed on 12-week MMTV-PyMT mouse lung metastasis and 3-week E0771
mammary fat pad primary tumor and lung metastasis. In addition, 6-week
MMTV-PyMT mice were examined for Rictor, Cytokeratin 8/18 (CK8/18), and
ERα expression and in vehicle and CX-5461 treated primary tumor tissues via IHC.
Progressive MMTV-PyMT primary tumors at 6-weeks, 8-weeks, and 12-weeks
were analyzed for Rictor expression via IHC. H&E and IHC images were taken
with a Nikon E600 Camera. Progressive MMTV-PyMT primary tumors at 6-weeks,
8-weeks and 12-weeks were examined for Pol I and Ki67 expression with immu-
nofluorescence. Briefly, slides were de-paraffinized, rehydrated, subjected to anti-
gen retrieval, and incubated with first primary antibody 1 h followed by secondary
antibody, then second primary and secondary treatment. Lastly, slides were
counterstained with Sudan black and immunofluorescence images were captured
with a Zeiss Confocal microscope. Vehicle and CX-5461 treated primary tumor
tissues were also analyzed for Snail1/2 and LC3 expression by immunofluorescence.
Lung metastases were counted by taking 25 sections from each lung, which were
stained with H&E to obtain the number of metastases (Fig. 4f), ANOVA, P < 0.02.
Mouse tissue sections from primary tumors and corresponding lung metastases
from at least 2 mice were IHC-stained from paraffin-embedded tissues from the
E0771 medullary adenocarcinomas mouse model48 and images of staining
expression levels were assayed in the same manner as the MMTV-PyMT model. All
MMTV-PyMT animal experimentation was approved by the local ethics com-
mittee for animal research (Stockholm Norra, license# N96/11 and Lund, license#
M142/13). All E0771 animal experimentation was performed in accordance with
institutional, IACUC and AAALAS guidelines, as detailed in our institutional
animal protocol #0709-666 A. FFPE (4 µm) sections were obtained from tissue
microarrays (TMA) consisting of normal mammary tissue and invasive tumor
from 106 patients and stained for Pol I. These studies were followed with whole
sections of breast cancer tissues from ER+ and TNBC (ER−/PR−/Her2−). Two
independent researchers performed blinded scoring of the invasive areas of tissue
samples as well as a surgical pathologist (JH), staining intensity was scored on a
scale of 0–4 (0 [no staining] – 4 [highest]) for quantification, scoring is represented
as an average from all 3 researchers. Figure 5c, Student’s t-test, P < 0.01. The
“Ethics Committee at the Karolinska Institutet”, Stockholm and the “Stockholm
Medical Biobank”, approved the study protocol. For all patients whose tumors were
included in the immunostaining studies, informed consent forms have been
approved and signed. See (Supplementary Table 1) for antibody details.
Relapse free survival analysis. Relapse Free Survival Analysis was performed
using the PROGgene V2 Prognostic Database (http://watson.compbio.iupui.edu/
chirayu/proggene/database/?url=proggene)80. Each analysis used “breast cancer”
as cancer type, “relapse” as survival measure, and bifurcated the gene expression
at the median. The data was not divided by or adjusted for any clinical status.
The relapse free status was then checked for expression levels of Polr1a and Ubtf,
P < 0.006.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data will be made available upon request from the authors. The RNA sequencing data
presented are available through the Sequence Read Archive BioProject: PRJNA531030.
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